Aficamten in Treatment of Hypertrophic Cardiomyopathy
Aficamten is a novel myocardial myosin inhibitor that safely reduces left ventricular outflow tract pressure by reducing cardiac contractility and improving diastolic function in patients with hypertrophic cardiomyopathy,thereby improving symptoms of heart failure in patients with hypertrophic cardiomyopathy.In 2022,aficamten received Breakthrough Therapy Designation from National Medical Products Administration and U.S.Food and Drug Administration for having a shorter plasma half-life and fewer drug interactions than the previous generation myocardial myosin inhibitor mavacamten.Based on data from completed and ongoing clinical trials,this paper reviews the progress of aficamten in the treatment of hypertrophic cardiomyopathy.
万方数据
维普
